Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: The adenosine hypothesis

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue SUPPL. 1, 1996, Pages 15-20

  Pasini, Franco Laghi ^a   Frigerio, Carlo ^a   Capecchi, Pier Leopoldo ^a   Ceccatelli, Linda ^a   Messa, Gian Luca ^a   Franchi, Massimo ^a   Di Perri, Tullio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Adenosine; Cytoplasmic free calcium; Defibrotide; Fibrinolysis; Neutrophils

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CALCIMYCIN; CALCIUM; CYTOCHROME C; DEFIBROTIDE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FURA 2 ACETOXYMETHYL ESTER; IONOMYCIN; IONOPHORE; LYSOSOME ENZYME; PHORBOL 13 ACETATE 12 MYRISTATE; PLASMINOGEN ACTIVATOR INHIBITOR; POLYDEOXYRIBONUCLEOTIDE; SODIUM CHLORIDE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THEOPHYLLINE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; CALCIUM TRANSPORT; CHEMOLUMINESCENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; EXTRACELLULAR CALCIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPOTHESIS; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE ACTIVATION; MALE; MODULATION; NORMAL HUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; VENOUS BLOOD;

ADENOSINE; ANTIFIBRINOLYTIC AGENTS; CALCIUM; CALCIUM CHANNEL BLOCKERS; ENDOTHELIUM, VASCULAR; HUMANS; NEUTROPHILS; POLYDEOXYRIBONUCLEOTIDES;

EID: 0029781302     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Mantovani M, G Prino, R Pescador: Activation of fibrinolytic process by a substance of polydeoxyribonucleotidic nature (fraction P). In: Strano A (Ed): Advances in Coagulation, Fibrinolysis, Platelet Aggregation and Atherosclerosis, C.E.P.I., Rome, 1978, p 274.
2. Mussoni L, C Evolví, MB Donati: Activation of plasma and vascular fibrinolytic activity by a polydeoxyribonucleotide substance fraction P in rats and rabbits. Thromb Haemostas 42:388-393, 1979.
3. Coccheri S, G Biagi, C Legnani, B Bianchini, F Grauso: Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 35:151-156, 1988.
4. Fareed J, JM Walenga, DA Hoppensteadt, A Kumar, ON Ulutin, U Cornelli: Pharmacologic profiling of defibrotide in experimental models. Semin Thromb Hemostas 14(Suppl):27-37, 1988
5. Niada R, M Mantovani, G Prino, R Pescador, GF Nardi: Antithrombotic activity of polydeoxyribonucleotides of mammalian origin in experimental animals. Thromb Haemostas 42:474(Abst 1162), 1979.
6. Avellone G, A Mandalà, A Pinto, A Martino, A Strano: Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs. Haemostasis 15 (Suppl 1):55-59, 1986.
7. Di Perri T, A Vittoria, GL Messa, R Cappelli: Defibrotide therapy for thrombophebitis. Controlled clinical trial. Haemostasis 16 (Suppl 1):42-47, 1986.
8. Cagnazzo D: Effectiveness of defibrotide for prophylaxis of deep venous thrombosis in gynecological clinical trial. Haemostasis 16 (Suppl 1):39-41, 1986.
9. Berti F, G Rossoni, C Omini, GC Folco, L Daffonchio, T Viganò, C Viganò: Defibrotide, an antithrombotic substance which prevents myocardial contracture in ischemic rabbit heart. Eur J Pharmacol 135:375-382, 1987.
10. Hohlfeld T, K Schrör: Protection by defibrotide of the reperfused ischemic pig heart. FASEB J 3:A581, 1989.
11. Niada R, R Porta, R Pescador, M Mantovani, G Prino: Cardioprotective effects of defibrotide in acute myocardial ischemia in the cat. Thromb Res 38:71-81, 1985.
12. Niada R, R Porta, R Tettamanti, R Pescador, M Mantovani, G Prino: Defibrotide in experimental myocardial ischemia in the cat: Effects on hemodynamics, energy metabolism and infarct size. Thromb Haemostas 58:101(Abst 353), 1987.
13. Schrör K, G Ackermann, T Hohlfeld, P Loebel, P Ney, H Schroeder, H Strobach: Endothelial protection by defibrotide, a new strategy for treatment of myocardial infarction? Z Kardiol 78 (Suppl 6):35-41, 1989.
14. Lucchesi BR, KM Mullane: Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol 26:201-224, 1986.
15. Niada R, M Mantovani, G Prino, R Pescador: Antithrombotic activity of a polydeoxyribonucleotide substance extracted from mammalian organs: A possible link with prostacyclin. Thromb Res 23:233-246, 1981.
16. 2-generation and antithrombotic activity of orally administered defibrotide. Pharmacol Res Commun 14:949-957, 1982.
17. Di Perri T, F Laghi Pasini, C Frigerio, PL Capecchi, GL Messa, M Franchi, F Landini, A Burresi, A Ghezzi, L Ceccatelli, L Volpi, P Blardi: New in vivo model to assess venous endothelial cell functions. Effect of defibrotide. Eur J Clin Pharmacol 37:351-357, 1989.
18. Di Perri T, F Laghi Pasini, C Frigerio, PL Capecchi, GL Messa, M Franchi, F Landini, A Burresi, L Ceccatelli, A Ghezzi, L Volpi: Usefulness of defibrotide in the treatment of vascular disorders: A clinical pharmacologic study. Semin Thromb Hemostas 17(Suppl): 85-95, 1991.
19. Belch JJ, M Chopra, S Hutchison, R Lorimer, RD Sturrock, CD Forbes, WE Smith: Free radical pathology in chronic arterial disease. Free Radic Biol Med 6:375-378, 1989.
20. Litt MA, RW Jeremy, HF Weisman, JA Winkelstein, LC Becker: Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Circulation 80:1816-1827, 1989.
21. Go LO, CE Murry, VJ Richard, GR Weischedel, RB Jennings, KA Reimer: Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury. Am J Physiol 255:H1188-H1198, 1988.
22. Romson JL, BG Hook, SL Kunkel, GD Abrams, MA Schork, BR Lucchesi: Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67:1016-1023, 1983.
23. Jolly SR, WJ Kane, BG Hook, GD Abrams, SL Kunkel, BR Lucchesi: Reduction of myocardial infarct size by neutrophil depletion: Effect of duration of occlusion. Am Heart J 112:682-690, 1986.
24. Romson JL, SR Jolly, BR Lucchesi: Protection of ischemic myocardium by pharmacologic manipulation of leukocyte function. Cardiovasc Res Reports 5:690-709, 1984.
25. Simpson PJ, SE Mitsos, A Ventura, KP Gallagher, JC Fantone, GD Abrams, MA Schork, BR Lucchesi: Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 113:129-137, 1987.
26. Mullane KM, N Read, JA Salmon, S Moncada: Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to myocardial salvage by antiinflammatory drugs. J Pharmacol Exp Ther 228:510-522, 1984.
27. Jolly SR, BR Lucchesi: Effect of BW755C in an occlusion-reperfusion model of ischemic myocardial injury. Am Heart J 106:8-13, 1983.
28. 2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn-Schmicdebergs Arch Pharmacol 331:125-130, 1985.
29. 2+-dependent neutrophil activation: Implications for its pharmacological activity in vascular disorders. Angiology 42:971-978, 1991.
30. ++ involving mechanism. Int J Tissue React 9:399-406, 1987.
31. Di Perri T, F Laghi Pasini: Effect of defibrotide on polymorphonuclear leukocytes: Modulation of calcium entry and availability. Semin Thromb Hemostas 14(Suppl):23-26, 1988.
32. Laghi Pasini F, PL Capecchi, A Orrico, L Ceccatelli, T Di Perri: Adenosine inhibits polymorphonuclear leukocyte in vitro activation: A possible role as an endogenous calcium entry blocker. J Immunopharmacol 7:203-215, 1985.
33. 1H-nuclear magnetic resonance relaxation investigations. Biophys J 52:729-733, 1987.
34. Laghi Pasini F, PL Capecchi, AL Pasqui, L Ceccatelli, S Mazza, A Gistri, T Di Perri: Adenosine system and cell calcium translocation: Interference of calcium channel blockers. Exp Gerontol 25: 383-391, 1990.
35. 1H-NMR relaxation investigations of membrane-bound drugs in vitro. Calcium-entry blockers and adenosine. J Biophys Chem 36:209-213, 1990.
36. Londos C, DMF Cooper, J Wolff: Subclass of external adenosine receptors. Proc Natl Acad Sci USA 77:2552-2554, 1980.
37. Van Calker D, M Müller, B Hamprecht. Adenosine regulates via two different receptors the accumulation of cAMP in cultured brain cells. J Neurochem 33:999-1005, 1979.
38. Afonso A, GS O'Brien: Inhibition of cardiovascular metabolic and hemodynamic effects of adenosine by aminophylline. Am J Physiol 219:1672-1674, 1970.
39. Daly JW, RF Bruns, SH Snyder: Adenosine receptors in the central nervous system: Relationship to the control actions of methylxanthines. Life Sci 28:2083-2097, 1981.
40. Barone D, L Salvetti: Receptor binding affinity profile of defibrotide. Pharmacol Res 22(Suppl 2):29, 1990 (abstr.)
41. Bianchi G, M Mantovani, G Prino, L Salvetti, D Barone: Possible agonistic interaction of defibrotide, a DNA derivative, with adenosine receptors "in vitro." International Symposium on Pharmacology of Purinergic Receptors. Implication for Drug Design. IUPHAR Satellite Symposium. Noordwijk, The Netherlands, July 6-8, 1990.
42. Baumann I, J Baumann, H Strobach: Responses to defibrotide in human platelets loaded with the fluorescent calcium inhibitor Indo-IAM. Deutsche Gesellschaft für Pharmakologie und Toxicologie, Abstracts of the 32nd Spring Meeting, Mainz, March 12-15, 1991.
43. Biagi G, C Legnani, G Rodorigo, S Coccheri: Modulation of arachidonate metabolite generation in human blood by oral defibrotide. Arzneim Forsch/Drug Res 41:511-514, 1991.